Chinook up as dosing starts in kidney disorder drug trial

Chinook Therapeutics

12/04/2022 15:24

** Shares of drug developer Chinook Therapeutics  KDNY.O 
rise 3.4% to $15.7
    ** Co starts dosing healthy participants in an early-stage
study on its experimental therapy for hyperoxaluria,
CHK-336 urn:newsml:reuters.com:*:nGNX77z5SG
    ** Hyperoxaluria, characterized by recurrent kidney and
bladder stones, is a rare genetic metabolic disorder resulting
from buildup of a substance called oxalate in the urinary
bladder
    ** Trial will test safety, tolerability, and
pharmacokinetics of CHK-336 in up to 104 healthy volunteers

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))